- Home
- RDHL
as 11-15-2024 9:47am EST
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
Upcoming Earnings Alert:
Get ready for potential market movements as Redhill Biopharma Ltd. RDHL prepares to release earnings report on 19 Nov 2024.
| Founded: | 2009 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 11.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 14.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -38.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.80 - $82.00 | Next Earning Date: | 11-19-2024 |
| Revenue: | $3,707,000 | Revenue Growth: | -89.63% |
| Revenue Growth (this year): | 224.9% | Revenue Growth (next year): | 82.69% |
Latest Redhill Biopharma Ltd. News
RDHL Breaking Stock News: Dive into RDHL Ticker-Specific Updates for Smart Investing
PR Newswire
18 days ago
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
TipRanks
23 days ago
RedHill Biopharma and Duke Collaborate on Opaganib Development
PR Newswire
24 days ago
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
PR Newswire
a month ago
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
TipRanks
a month ago
RedHill Biopharma Secures Opaganib COVID-19 Patent
PR Newswire
a month ago
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
MT Newswires
2 months ago
RedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib
PR Newswire
2 months ago
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
Compare RDHL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RDHL Redhill Biopharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.